The candidacy of PKR as a therapeutic target has been suggested in a number of other diseases, including neurodegeneration, obesity, diabetes and influenza [26], [35], [36], [37], [38], [39]. This evidence concerns the gene EIF2AK2 and obesity due to melanocortin 4 receptor deficiency.